Reduce the appearance of under-eye bags and dark circles with the DIBI Acid Infusion No-Age Restructuring Cream SPF30. This luxury cream soothes and moisturises your skin, and creates a visible lifting effect of the eyelids. Its pure Glycyrrhetinic Acid + Vitamin F rich formula also helps you protect the skin from signs of chrono- and photo-ageing.
Rich cream created to shield the skin from photo- and chrono-aging symptoms.
Contains glycyrrhetinic acid, a calming active ingredient that strengthens the skin’s defences, and vitamin F, which is a good source of vital fatty acids to preserve the hydrolipidic barrier of the skin. It without colourants.
A thick day cream with SPF 30 called DIBI No Age Restructuring Cream was created to shield the skin from ageing symptoms. contains glycyrrhetinic acid, a calming active component that strengthens skin defences, as well as vitamin F, which is a source of vital fatty acids and helps to maintain the hydrolipidic barrier of the skin. This restructuring cream also contains Peptide 8, which makes skin more protected, moisturised, and younger-looking while also reducing the visible indications of ageing. has an SPF of 30, however you should still use an SPF throughout the day to defend against UV radiation.
No-Age Restructuring Cream SPF30 is available in 50ml.
Like DIBI? Get your gift set today!
Free shipping for all Gift Voucher orders.
Delivery for all Product orders is £3.95.
We send all items first class.
-Poly-functional complex molecule that integrates the natural defence mechanisms of the skin’s mother cells.
-It supports the proteins involved in the production of collagen and elastin, to create a visible lifting effect.
-Soothing and moisturising properties.
-Smoothing and lifting action of the eyelids, reducing the visibility of under-eye bags and dark circles.
Available in 50ml.
Apply to the face and neck during the day, massaging until fully absorbed.
– GLYCYRRHETINIC ACID
– VITAMIN F
– PEPTIDE 8
You must be logged in to post a review.
Reviews
There are no reviews yet.